Genesis Health Review

What Genesis Health charges

• Sermorelin: $175 — TERM-GATED AND SELF-CONTRADICTING: the product page prints "$175 per month *" with the asterisk resolving, on the same page, to "*With annual plan." The site-wide rail on that same page prints "Sermorelin Injections — From $175 first month". The identical figure is presented as a first-month rate in one place and an annual-plan rate in the other
• Sermorelin: $95 — printed as "Sermorelin ODT — In stock — Save $50 on your first order — $95 per month *", with "*With annual plan." on the same page. An orally-disintegrating tablet, not an injection, and eighty dollars below the injectable figure
• NAD+: $165 — read from the site-wide rail as "NAD+ Injections — From $165 first month". ⛔ A first-month rate by its own label; the standing rate is not published on the pages read, and this seller prints its other rail figure under a contradictory condition on the product page, so the rail cannot be treated as settled

One figure, two incompatible conditions, one page

The site-wide rail that renders on every product page advertises the growth-hormone injection from a figure, described as a first-month rate. The product page beneath that rail gives the same figure with an asterisk, and resolves the asterisk on the same page: with an annual plan.

A first-month promotional rate lapses after four weeks. An annual-plan rate requires a twelve-month commitment. They are opposite claims about the same number and both are rendered in the same document.

This site records the figure as one that is not a monthly rate and writes both conditions into the qualifier, because there is no defensible basis for choosing between two statements the seller makes simultaneously.

The coenzyme figure appears only in the rail, described as a first-month rate. Given what the rail does to the other figure, this site does not treat that description as settled either, and says so in the qualifier.

Resolving an asterisk on the page is still good practice

It is worth separating two things here. Putting the asterisk's meaning on the same page as the asterisk is better than burying it in a terms document, which several sellers in this batch do.

The problem is not where the condition is. It is that the seller publishes a second, different condition for the same figure a few hundred pixels above it.

So this seller is simultaneously more transparent than the median about what an asterisk means and less reliable than the median about which condition applies.

A reader who reads only the rail and a reader who reads only the product page come away with different beliefs about how long the price lasts.

Two routes, priced apart

The growth-hormone peptide is sold as an injection and as an orally-disintegrating tablet, at figures well apart, on separate product pages with separate stock markers.

That is the right treatment. A dissolvable tablet and a subcutaneous injection are different products and a reader chooses between them; averaging them into one programme price would hide the choice.

Both carry the same annual-plan asterisk, so both are recorded as figures that are not monthly rates.

The catalogue also names a nasal spray, a face cream and an antioxidant, none of which carried a figure on the pages read.

A warning letter issued the same day as a sibling's

The privacy policy names the operating company plainly. Screened by that name against the regulator's warning-letter index, it returns a letter concerning false and misleading claims in a telehealth channel.

Its reference number is one digit apart from a letter issued to another seller on this roster, and both carry the same issue date. Two unrelated brands, consecutive numbers, one enforcement day.

The letter is disclosed on the row, linked, and does not move this seller's score or position here.

No dispensing pharmacy is named, no certificate of analysis exists on the pages read, and no state coverage list is published.

FDA disclosure

Genesis Health received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.

How we verified this

• Loaded both growth-hormone product pages and the privacy policy with a full browser user-agent, printing the effective URL beside the requested one on each.
• Ran a nonsense-path control on the host in the same run, which returned a clean not-found status with a small body.
• Joined the page's text nodes before matching any figure, so a price split across elements could not read as an absence.
• Read the rail and the product body in the same fetch and recorded both conditions attached to the same figure rather than choosing one.
• Recorded both growth-hormone figures as ones that are not monthly rates, on the strength of the annual-plan asterisk resolved on their own pages.
• Declined to treat the rail's first-month description of the coenzyme figure as settled, and said so in that row's qualifier, because the rail is known on this site to disagree with the page beneath it.
• Read the privacy policy for the operating company's registered name.
• Screened the operating company and the brand against the regulator's warning-letter index, with a nonsense query as a control in the same run, and compared the returned reference number against the other letters found in this batch.